(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; pyridine-4-carbohydrazide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; pyridine-4-carbohydrazide
• 英文别名: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;pyridine-4-carbohydrazide
• 化学式: C44H76N4O14
• 分子量: 885.1
• InChiKey: RZRYHSJCVSJBHJ-AZFLODHXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.12
• 重原子数：
  62
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  251
• 氢给体数：
  6
• 氢受体数：
  17

文献信息

• [EN] HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DE PROTÉINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017175147A1

  公开（公告）日：2017-10-12

  Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

  揭示了具有化学式（I-N）的化合物，其中q、r、s、A、B、C、RA1、RA2、RB1、RB2、RC1、RC2、R3、R4、R5、R6、R14、R15、R16和R17如本文所定义，或其互变异构体，或其盐，特别是其药用可接受盐。
• [EN] MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV<br/>[FR] MODULATEURS DE STIMULATEUR DES GÈNES (STING) D'INTERFÉRON UTILES DANS LE TRAITEMENT DU VIH
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019069269A1

  公开（公告）日：2019-04-11

  Disclosed are compounds having the formula: (I-N) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof, along with combinations thereof, all of which are useful in HIV therapies.

  揭示了具有以下式的化合物：(I-N)其中q、r、s、A、B、C、RA1、RA2、RB1、RB2、RC1、RC2、R3、R4、R5、R6、R14、R15、R16和R17如本文所定义，或其互变异构体，或其盐，特别是其药用可接受盐，以及其组合物，所有这些在HIV疗法中是有用的。
• [EN] MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)<br/>[FR] MODULATEURS DE STIMULATEUR DES GÈNES (STING) DE L'INTERFÉRON
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019069270A1

  公开（公告）日：2019-04-11

  Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

  揭示的化合物具有以下公式：(I) 其中 q、r、s、A、B、C、RA1、RA2、RB1、RB2、RC1、RC2、R3、R4、R5、R6、R14、R15、R16、R17、Rx 和 Ry 如本文所定义，或其互变异构体，或其盐，特别是其药学上可接受的盐。
• [EN] BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING<br/>[FR] DÉRIVÉS DE BENZOTHIOPHÈNE, DE THIÉNOPYRIDINE ET DE THIÉNOPYRIMIDINE POUR LA MODULATION DE STING
  申请人：CTXT PTY LTD

  公开号：WO2021009365A1

  公开（公告）日：2021-01-21

  A compound of formula (I): wherein: Y is (CH2)n, where n is from 2 to 4; W1 and W11 are independently selected from OH and ORP, where RP is Me or Et.

  式（I）的化合物：其中：Y为（CH2）n，其中n为2至4；W1和W11分别选择自OH和ORP，其中RP为Me或Et。
• [EN] BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING<br/>[FR] DÉRIVÉS DE BENZOTHIOPHÈNE, DE THIÉNOPYRIDINE ET DE THIÉNOPYRIMIDINE PERMETTANT LA MODULATION D'UNE PIQÛRE
  申请人：CTXT PTY LTD

  公开号：WO2021009362A1

  公开（公告）日：2021-01-21

  A compound of formula (I); wherein: W is O or NH; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH; the remainder of R A, RB, RC and RD, (if present) are H; RN1 is H or Me; one of RC2 and RC3 is C(=O)NH2; the other is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl; RC1 and RC4 are independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl.

  化合物的化学式（I）；其中：W为O或NH；A1为CRA或N；A2为CRB或N；A3为CRC或N；A4为CRD或N；其中A1、A2、A3和A4中最多有两个可以是N；RA、RB、RC和RD中的一个或两个（如果存在）从H、F、Cl、Br、Me、CF3、环丙基、氰基、OMe、OEt、CH2OH、CH2OMe和OH中选择；RA、RB、RC和RD的其余部分（如果存在）为H；RN1为H或Me；RC2和RC3中的一个为C（=O）NH2；另一个从H、Cl、F、Br、Me、OMe、OEt、氰基、CF3、CH2OH、CH2OMe、C2-4烯基和C5杂环烷基中选择；RC1和RC4分别从H、Cl、F、Br、Me、OMe、OEt、氰基、CF3、CH2OH、CH2OMe、C2-4烯基和C5杂环烷基中独立选择。